AllianceBernstein
AVTX icon

AllianceBernstein’s Avalo Therapeutics AVTX Stock Holding History

AllianceBernstein’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Buy
+1,260,689
New +$19.9M 0.01% 862
2022
Q2 		– Sell
-7
Closed -$14K – 3271
2022
Q1 		$14K Hold
7
– – ﹤0.01% 3228
2021
Q4 		$32K Hold
7
– – ﹤0.01% 3259
2021
Q3 		$42K Hold
7
– – ﹤0.01% 3233
2021
Q2 		$62K Buy
7
+1
+17% +$8.38K ﹤0.01% 3269
2021
Q1 		$54K Hold
6
– – ﹤0.01% 3193
2020
Q4 		$47K Hold
6
– – ﹤0.01% 3145
2020
Q3 		$41K Sell
6
-2
-25% -$15K ﹤0.01% 3130
2020
Q2 		$58K Buy
+8
New +$58.1K ﹤0.01% 3150

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

AllianceBernstein's AVTX Position: Q2 2026 in Review

AllianceBernstein opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 1,260,689 shares worth $23.3M. The stake represents 0.01% of the portfolio and ranks #862 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in AVTX as recently as Q1 2022.

AllianceBernstein first reported a position in AVTX in Q2 2020 and has held it in 9 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • AllianceBernstein held 1,260,689 shares of Avalo Therapeutics worth $23.3M as of Q2 2026.
  • Avalo Therapeutics was a new AllianceBernstein position in Q2 2026.
  • Avalo Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #862 holding.
  • AllianceBernstein first reported a position in Avalo Therapeutics in Q2 2020 and has held it in 9 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.